CNR1: Cannabinoid receptor 1
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
G protein-coupled receptor for endogenous cannabinoids (eCBs), including N-arachidonoylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG), as well as phytocannabinoids, such as delta(9)-tetrahydrocannabinol (THC).
- Drugs that act on it: 13
- Approved: 4
- In phases 1 to 3: 9
- Sponsors: 10
Who Is On It, and How Far Along
Every drug ChEMBL records acting on CNR1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule
- Antibody
Approved4
Phase 33
Phase 25
Phase 11
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Sanofi215%
- Alkem Laboratories18%
- Bausch Health18%
- Bristol-Myers Squibb18%
- Jazz Pharmaceuticals18%
- Merck & Co. (MSD)18%
- Novartis Pharmaceuticals18%
- Pfizer18%
- Sinfatin S.L18%
- Skye Bioscience, Inc.18%
Modalities
Drugs on this target by ChEMBL molecule type.
- Small molecule1292%
- Antibody18%
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| Cannabidiol | Approved | Jazz Pharmaceuticals | Small molecule | Negative allosteric modulator | Cannabinoid CB1 receptor negative allosteric modulator | 146 | — |
| Dronabinol | Approved | Alkem Laboratories | Small molecule | Agonist | Cannabinoid CB1 receptor agonist | 85 | — |
| Rimonabant | Approved | Sinfatin S.L | Small molecule | Antagonist | Cannabinoid CB1 receptor antagonist | 4 | Withdrawn |
| Nabilone | Approved | Bausch Health | Small molecule | Agonist | Cannabinoid CB1 receptor agonist | 2 | — |
| Drinabant | Phase 3 | Sanofi | Small molecule | Antagonist | Cannabinoid CB1 receptor antagonist | 0 | — |
| Otenabant | Phase 3 | Pfizer | Small molecule | Antagonist | Cannabinoid CB1 receptor antagonist | 0 | — |
| Taranabant | Phase 3 | Merck & Co. (MSD) | Small molecule | Inverse agonist | Cannabinoid CB1 receptor inverse agonist | 0 | — |
| Nimacimab | Phase 2 | Skye Bioscience, Inc. | Antibody | Negative allosteric modulator | Cannabinoid CB1 receptor negative allosteric modulator | 1 | — |
| AZD2207 | Phase 2 | — | Small molecule | Antagonist | Cannabinoid CB1 receptor antagonist | 0 | — |
| Ibipinabant | Phase 2 | Bristol-Myers Squibb | Small molecule | Antagonist | Cannabinoid CB1 receptor antagonist | 0 | — |
| Nonabine | Phase 2 | — | Small molecule | Agonist | Cannabinoid CB1 receptor agonist | 0 | — |
| Surinabant | Phase 2 | Sanofi | Small molecule | Antagonist | Cannabinoid CB1 receptor antagonist | 0 | — |
| SAD448 | Phase 1 | Novartis Pharmaceuticals | Small molecule | Agonist | Cannabinoid CB1 receptor agonist | 0 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 20 in all, from ClinicalTrials.gov.Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Obesity disorder
- 0.64
- Epilepsy
- 0.54
- Dravet syndrome
- 0.53
- Seizure
- 0.52
- Cancer
- 0.50
- Encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy
- 0.50
- Nausea
- 0.50
- Anorexia
- 0.48
- Insomnia
- 0.46
- Type 2 diabetes mellitus
- 0.42
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL218, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P21554, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets